RoslinCT is a leading UK-based cell therapy CDMO focused on providing services for companies developing cell-based therapeutic products for both European and U.S. clinical trials. The company operates a fully licensed, 40,000-sq.-ft. GMP manufacturing facility at the Edinburgh BioQuarter and is equipped for analysis, cell banking, in-process and final product QC testing, QP batch certification, GMP storage, and controlled temperature distribution. A subsequent 2023 merger with Lykan Bioscience more than doubled their capacity, adding a 64,000-sq.-ft. facility in Hopkinton, Massachusetts, to the combined companies.